Pancreatic Cancer Research

ResearcherUniversität UlmActive in the last 2 years

Lukas Perkhofer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0484-0974; OpenAlex author ID A5034891779. Sources: OpenAlex.

Their work

Papers
24 (first author 6, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
77
Papers, trials and grants by year

2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 4 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 24

  1. DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer. Co-author DOI 10.1002/advs.202417606↗
  2. ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
  3. Homologous Repair-Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy. Last author DOI 10.1002/ueg2.12773↗
  4. Pancreatic cancer patient-derived organoids capture therapy response and tumor evolution First author DOI 10.1101/2025.04.24.650216↗
  5. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  6. Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling. Last author DOI 10.1159/000521631↗
  7. The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. Last author DOI 10.3390/cancers14010217↗
  8. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. First author DOI 10.1136/gutjnl-2019-319970↗
  9. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Co-author DOI 10.1136/gutjnl-2019-319984↗
  10. RINT1 Regulates SUMOylation and the DNA Damage Response to Preserve Cellular Homeostasis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-2633↗
  11. A Prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Co-author DOI 10.3390/cancers13112539↗
  12. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response. Co-author DOI 10.1177/2050640620905183↗
  13. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. Co-author DOI 10.3390/cells9092110↗
  14. Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer. Co-author DOI 10.1159/000497291↗
  15. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, r… Co-author DOI 10.1186/s12885-018-5183-y↗
  16. Precision medicine meets the DNA damage response in pancreatic cancer. Co-author DOI 10.18632/oncoscience.392↗
  17. Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent - a multicenter survey in Germany and review of the literature. Co-author DOI 10.1055/s-0043-105502↗
  18. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Co-author DOI 10.1158/0008-5472.can-17-0634↗
  19. Tbx3 fosters pancreatic cancer growth by increased angiogenesis and activin/nodal-dependent induction of stemness. Co-author DOI 10.1016/j.scr.2016.08.007↗
  20. DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12885-016-2052-4↗
  21. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. First author DOI 10.1038/ncomms8677↗
  22. [Therapy in pancreatic cancer - and still it moves along!]. First author DOI 10.1055/s-0041-101154↗
  23. Smarter drugs emerging in pancreatic cancer therapy. First author DOI 10.1093/annonc/mdu013↗
  24. Pancreatic Cancer: Progress in Systemic Therapy. Co-author DOI 10.1159/000380785↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thomas Theodor Werner Seufferlein · 20 shared papers, 2014–2026 · strength 2.12
  2. Alexander Kleger · 16 shared papers, 2014–2026 · strength 1.88
  3. Thomas Jens Ettrich · 13 shared papers, 2014–2025 · strength 1.56
  4. Johann Gout · 11 shared papers, 2018–2026 · strength 1.56
  5. Élodie Roger · 9 shared papers, 2020–2026 · strength 1.37
  6. Alica K. Beutel · 6 shared papers, 2019–2025 · strength 0.88
  7. Frank Arnold · 6 shared papers, 2020–2026 · strength 0.78
  8. Dharini Srinivasan · 3 shared papers, 2025–2026 · strength 0.58
  9. Hans Armin Kestler · 4 shared papers, 2021–2025 · strength 0.47
  10. Marko Kornmann · 4 shared papers, 2018–2025 · strength 0.47
  11. Niklas Sturm · 2 shared papers, 2022 · strength 0.46
  12. Martin Müller · 5 shared papers, 2016–2021 · strength 0.43
  13. Christopher J. Halbrook · 2 shared papers, 2025–2026 · strength 0.42
  14. Pierre‐Olivier Frappart · 5 shared papers, 2017–2021 · strength 0.42
  15. Michael Karl Melzer · 2 shared papers, 2026 · strength 0.40
  16. Matthias J. Löhr · 2 shared papers, 2026 · strength 0.40
  17. Patrick Christian Hermann · 4 shared papers, 2016–2026 · strength 0.39
  18. Karolin Walter · 4 shared papers, 2016–2021 · strength 0.31
  19. Roland Rad · 2 shared papers, 2021–2026 · strength 0.27
  20. Michael Geißler · 3 shared papers, 2016–2023 · strength 0.23
  21. Hana Algül · 3 shared papers, 2017–2023 · strength 0.23
  22. Chantal Allgöwer · 1 shared paper, 2026 · strength 0.22
  23. Peter Möller · 1 shared paper, 2026 · strength 0.22
  24. Felix Jakob Hüttner · 1 shared paper, 2022 · strength 0.20
  25. Andreas Wolfgang Berger · 3 shared papers, 2016–2018 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.